DB06161InvestigationalProtein Based Therapies
Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.
- Primary indication
- Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.Curator reviewed
- Also known as
- 1-193-BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN (132-ALANINE) (HUMAN REDUCED) · 1-193-BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN (132-ALANINE) (HUMAN) · BACTERICIDAL PERMEABILITY-INCREASING PROTEIN OPEBACAN [MI]
- Code names
- RBPI-21
Resolves to
Compound
What you can answer from here — as of July 18, 2023
Which companies are running trials of Opebacan, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account